29 January, 2014

13:15 - 14:45UTC+01:00

Technical Briefing: Launch Event of ‘Assessing the Value of Biopharmaceutical Innovation in Key Therapy Areas in Middle Income Countries’

Technical Briefing: Launch Event of ‘Assessing the Value of Biopharmaceutical Innovation in Key Therapy Areas in Middle Income Countries’

World Intellectual Property Organization Room B Chemin des Colombettes 34

IFPMA rolled out an independent study, Assessing the Value of Biopharmaceutical Innovation in Key Therapy Areas in Middle Income Countries, during the recent SCP meeting in Geneva. Conducted by Charles River Associates (CRA), the study demonstrates the value that innovative medicines have for patients and society by enhancing treatment options and reducing overall healthcare costs.
Despite these benefits, the report concludes that there remains enormous untapped potential of adopting innovative medicines more widely in middle-income countries. This can be achieved by national prioritization, investments in healthcare infrastructure and building better epidemiological and cost databases for effective evaluation of therapies.
Tim Wilsdon, CRA Vice President, presented the findings to an audience of over 70 participants and a panel of two commentators elaborating on the value of medicines. Panelists included Dr. Evelyne Sauty, Director of Clinical and Medical Affairs at MSD and Mr. Greg Perry, Executive Director of the Medicines Patent Pool. IFPMA’s Andrew Jenner moderated the event.
The CRA study focused on five therapy areas: coronary heart disease (CHD), depression, diabetes II, HIV/AIDS, and rotavirus infection. Wilsdon shared research showing that significant decreases in hospitalization costs and mortality rates in countries like Brazil and Australia can be attributed to the introduction of selected medicines. The panelists complemented CRA’s findings and provided their experiences. Dr. Sauty highlighted R&D challenges and complexity by illustrating how MSD researched, developed, and provided a new vaccine preventing rotavirus, while Mr. Perry cited development of certain HIV/AIDS treatments in addressing the collaborative nature of many innovation programs. Finally, to inform and enrich SCP discussions on patent and health, this study provides significant empirical evidence by considering the wider value of medicines rather than focusing on cost and price alone.

13.00 – 13.15

Sandwich lunch


13.15 – 13.45

Report Launch
Tim Wilsdon
Vice President, Charles River Associates


13.45 – 14.15

Commentators
Evelyne Sauty
Director, Clinical & Medical Affairs,
Central & Eastern Europe, Merck Sharp and Dohme
Greg Perry
Executive Director, The Medicines Patent Poo


14.15 – 14.45

Questions and Answers
Moderator
Andrew Jenner
Executive Director, Corporate Strategy and Legal
Affairs, IFPMA


Tim Wilsdon

Tim Wilsdon

Vice President, Charles River Associates

Tim Wilsdon focuses on projects involving the pharmaceuticals sector and the retail financial services market. As a vice president in CRA’s London office, Mr. Wilsdon is responsible for leading many pharmaceuticals projects in Europe. He commonly talks at European conferences on issues to do with pricing and reimbursement and the economics of innovation.

Recently he has completed studies for PhRMA, LIF, and PIASA on how pharmaceutical markets could be reformed to work more efficiently. Previously, he was responsible for managing an assignment for the European Commission determining whether there was a global crisis in innovation. He has worked on a series of global pharmaceutical projects, recent examples include projects investigating the potential for launching a new Alzheimers and arthritis product and the likely impact of bio-similars in the growth hormone market. He managed an ex-post assessment of launch strategy for a cardiovascular product in the UK, Germany, Belgium, and the Nordic countries, and he led CRA’s European efforts to support global launches in hypertension and antibiotics. Mr. Wilsdon has managed a series of policy projects in the pharmaceuticals sector, including the development of a quantitative model on parallel trade in Europe and numerous projects for the UK’s Department of Health assessing the return on capital, the return on sales, and comparing the PPRS to other European regulatory schemes.

Mr. Wilsdon also focuses on projects in the financial services sector. He is responsible for CRA’s work in retail financial services in the London office and leads much of the team’s quantitative economics. His experience includes leading a numbers of major studies on behalf of the Financial Services Authority into the regulation of wholesales insurance and advice on packaged investment products. He was also responsible for significant assignments for the Association of British Insurers and the European Commission as well as leading insurance companies and fund managers.

Evelyne Sauty

Evelyne Sauty

Director, Clinical & Medical Affairs, Central & Eastern Europe, Merck Sharp and Dohme

2011 - Present
Director, Medical Affairs Vaccines EUCAN Region - Merck
2008 - 2012
DIRECTOR, CLINICAL& MEDICAL AFFAIRS EUROPE GSK Bio, Paediatric vaccines - GlaxoSmithKline
2005 - 2008
SCIENTIFIC DIRECTOR CNS&Rheumatology - GlaxoSmithKline
1990 - 1991
Essec Business School Paris
1982 - 1989
Docteur en Médecine - MD

Greg Perry

Greg Perry

Executive Director, Medicines Patent Pool

Greg Perry joined the Medicines Patent Pool with over 20 years of experience in pharmaceutical and intellectual property policy issues. Greg has an extensive track record of high-level advocacy with governments, international organizations, pharmaceutical stakeholders and NGOs and has a personal commitment to improving public health. Greg founded the European Generic Medicines Association in 1993 and has been its Director General since 1999. He is also a founding member of the International Generic Pharmaceutical Alliance and has been on its management committee since 1997. Prior to joining the generic industry, Greg advised corporate and non-governmental organizations on European Union legislation and policy.
Greg was awarded the Golden Cross of Merit of the Republic of Poland in 2004 for contribution to industry and European integration. He was granted an honorary life fellowship of the Organization for Professionals in Regulatory Affairs (TOPRA) in 2005 for contributions to European pharmaceutical regulatory issues. Greg is also member of the Standing Advisory Committee before the European Patent Office. Typically, Greg has been open with the IFPMA and the industry and wants to build the relationship between the industry and the Geneva community.

29th Jan 2014

13:15 - 14:45 UTC+01:00

World Intellectual Property Organization Room B Chemin des Colombettes 34